The facts
Third-quarter organic sales rose 2.6%, with revenue of about £2.89 billion, according to interactive investor's report. Organic growth is distinct from a change in total reported revenue. [2]
Reuters reported that changes to China's raw-material classifications forced Haleon to suspend imports of affected Centrum products and alter its portfolio. [1]
Haleon kept its expectation for high-single-digit annual adjusted operating-profit growth and announced a £500 million share buyback, interactive investor reported. [2]
Still unconfirmed
- The complete issuer financial PDF was not retrievable through the checked public endpoints. Forecasts remain conditional.
Sources
References support the numbered facts above. Source checks: 29 Oct 2026, 23:12 UTC.
Haleon's dated RNS notice was read, but it links to the full financial statement rather than containing the figures. The issuer page served an empty application shell and the linked statement PDF was inaccessible. The core cut and stated reasons were verified in two independently owned actual reports; no AI summary was used as evidence.
- Haleon shares tumble as weak flu medicine demand, China woes prompt outlook cut
Reuters via WHBL · Reporting · 29 Oct 2026
Actual report by Simone Lobo and Raechel Thankam Job read, including management statements. The timestamped London intraday move is not substituted for an ADR or closing return.
- Haleon shares crash in response to Q3 update
interactive investor / Aberdeen · Reporting · 29 Oct 2026
Actual original company-results report read. Separately owned from Reuters and Haleon. Analyst recommendations, investment opinions and price targets are omitted.